Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
%max (binding) | Maximum response towards cloned human 5HT1A receptor | ChEMBL. | 16302814 | |
%max (binding) | 0 | Maximum response towards cloned human 5HT1A receptor | ChEMBL. | 16302814 |
GI50 (functional) | = 2 uM | Cytotoxic activity on human PC3 prostate cancer cells by SRB assay | ChEMBL. | 16302814 |
GI50 (functional) | = 2 uM | Cytotoxic activity on human PC3 prostate cancer cells by SRB assay | ChEMBL. | 16302814 |
LC50 (functional) | = 63.1 uM | Cytotoxic activity on human PC3 prostate cancer cells by SRB assay | ChEMBL. | 16302814 |
LC50 (functional) | = 63.1 uM | Cytotoxic activity on human PC3 prostate cancer cells by SRB assay | ChEMBL. | 16302814 |
Log Ki (binding) | Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from cloned human 5HT1A receptor expressed in HeLa cells | ChEMBL. | 16302814 | |
Log Ki (binding) | Displacement of [3H]prazosin from cloned human ADRA1D expressed in CHO cells | ChEMBL. | 16302814 | |
Log Ki (binding) | Displacement of [3H]prazosin from cloned human ADRA1B expressed in CHO cells | ChEMBL. | 16302814 | |
Log Ki (binding) | Displacement of [3H]prazosin from cloned human ADRA1A expressed in CHO cells | ChEMBL. | 16302814 | |
Log Ki (binding) | 0 | Displacement of [3H]prazosin from cloned human ADRA1A expressed in CHO cells | ChEMBL. | 16302814 |
Log Ki (binding) | 0 | Displacement of [3H]prazosin from cloned human ADRA1B expressed in CHO cells | ChEMBL. | 16302814 |
Log Ki (binding) | 0 | Displacement of [3H]prazosin from cloned human ADRA1D expressed in CHO cells | ChEMBL. | 16302814 |
Log Ki (binding) | 0 | Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from cloned human 5HT1A receptor expressed in HeLa cells | ChEMBL. | 16302814 |
pD2 (binding) | Agonist efficacy towards cloned human 5HT1A receptor by [35SGTP]gammaS binding in HeLa cells | ChEMBL. | 16302814 | |
pD2 (binding) | 0 | Agonist efficacy towards cloned human 5HT1A receptor by [35SGTP]gammaS binding in HeLa cells | ChEMBL. | 16302814 |
pKb (functional) | = 8.17 | ADRA1A blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat prostatic vas deferens | ChEMBL. | 16302814 |
pKb (functional) | = 8.62 | ADRA1B blocking activity assessed by antagonism of (-)-phenylephrine induced contractions on isolated rat spleen | ChEMBL. | 16302814 |
pKb (functional) | = 9.14 | ADRA1D blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat thoracic aorta | ChEMBL. | 16302814 |
pKb (functional) | = 8.17 | ADRA1A blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat prostatic vas deferens | ChEMBL. | 16302814 |
pKb (functional) | = 8.62 | ADRA1B blocking activity assessed by antagonism of (-)-phenylephrine induced contractions on isolated rat spleen | ChEMBL. | 16302814 |
pKb (functional) | = 9.14 | ADRA1D blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat thoracic aorta | ChEMBL. | 16302814 |
TGI (functional) | = 17.8 uM | Cytotoxic activity on human PC3 prostate cancer cells by SRB assay | ChEMBL. | 16302814 |
TGI (functional) | = 17.8 uM | Cytotoxic activity on human PC3 prostate cancer cells by SRB assay | ChEMBL. | 16302814 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.